Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin effect on mitochondrial function in paroxysmal atrial fibrillation
IRCT20240623062224N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of empagliflozin in Atrial fibrillation (AFib) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: total reactive oxygen species activity, total antioxidant capacity and 3 more. Started Jul 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on IRCT20240623062224N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240623062224N1.